Skip to main content
Top
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Relevance of cyclin D1b expression and CCND1polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma

Authors: Sophie Krieger, Juliette Gauduchon, Mikel Roussel, Xavier Troussard, Brigitte Sola

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

The CCND1 gene generates two mRNAs (cyclin D1a and D1b) through an alternative splicing at the site of a common A/G polymorphism. Cyclin D1a and b proteins differ in their C-terminus, a region involved in protein degradation and sub-cellular localization. Recent data have suggested that cyclin D1b could be a nuclear oncogene. The presence of cyclin D1b mRNA and protein has been studied in two hemopathies in which cyclin D1 could be present: multiple myeloma (MM) and mantle cell lymphoma (MCL). The A/G polymorphism of CCND1 has also been verified in a series of patients.

Methods

The expression of cyclin D1 mRNA isoforms has been studied by real-time quantitative PCR; protein isoforms expression, localization and degradation by western blotting. The CCND1 polymorphism was analyzed after sequencing genomic DNA.

Results

Cyclin D1 mRNA isoforms a and b were expressed in mantle cell lymphoma (MCL) and multiple myeloma (MM). Cyclin D1b proteins were present in MCL, rarely in MM. Importantly, both protein isoforms localized the nuclear and cytoplasmic compartments. They displayed the same short half-life. Thus, the two properties of cyclin D1b recognized as necessary for its transforming activity are missing in MCL. Moreover, CCND1 polymorphism at the exon/intron boundary had no influence on splicing regulation in MCL cells.

Conclusion

Our results support the notion that cyclin D1b is not crucial for the pathogenesis of MCL and MM.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM: The proliferation gene signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003, 3: 185-197. 10.1016/S1535-6108(03)00028-X.CrossRefPubMed Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM: The proliferation gene signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003, 3: 185-197. 10.1016/S1535-6108(03)00028-X.CrossRefPubMed
2.
go back to reference Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J: Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005, 106: 296-303. 10.1182/blood-2005-01-0034.CrossRefPubMedPubMedCentral Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J: Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005, 106: 296-303. 10.1182/blood-2005-01-0034.CrossRefPubMedPubMedCentral
3.
go back to reference Inaba T, Matsushime H, Valentine M, Roussel MF, Sherr CJ, Look AT: Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics. 1992, 13: 565-574. 10.1016/0888-7543(92)90126-D.CrossRefPubMed Inaba T, Matsushime H, Valentine M, Roussel MF, Sherr CJ, Look AT: Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics. 1992, 13: 565-574. 10.1016/0888-7543(92)90126-D.CrossRefPubMed
4.
go back to reference Betticher C, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J: Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995, 11: 1005-1011.PubMed Betticher C, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J: Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995, 11: 1005-1011.PubMed
5.
go back to reference Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12: 3499-3511.CrossRefPubMedPubMedCentral Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12: 3499-3511.CrossRefPubMedPubMedCentral
6.
go back to reference Alt JR, Cleveland JL, Hannink M, Diehl JA: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2000, 96: 906-913. Alt JR, Cleveland JL, Hannink M, Diehl JA: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2000, 96: 906-913.
7.
go back to reference Lu F, Gladden AB, Diehl JA: An alternative spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogenes. Cancer Res. 2003, 63: 7056-7061.PubMed Lu F, Gladden AB, Diehl JA: An alternative spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogenes. Cancer Res. 2003, 63: 7056-7061.PubMed
8.
go back to reference Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES: Cyclin D1 splice variants. J Biol Chem. 2003, 278: 30339-30347. 10.1074/jbc.M303969200.CrossRefPubMed Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES: Cyclin D1 splice variants. J Biol Chem. 2003, 278: 30339-30347. 10.1074/jbc.M303969200.CrossRefPubMed
9.
go back to reference Holley SL, Heighway J, Hoban PR: Induced expression of human CCND1 alternative transcripts in mouse Cyl-1 knockout fibroblasts highlights functional differences. Int J Cancer. 2005, 114: 364-370. 10.1002/ijc.20750.CrossRefPubMed Holley SL, Heighway J, Hoban PR: Induced expression of human CCND1 alternative transcripts in mouse Cyl-1 knockout fibroblasts highlights functional differences. Int J Cancer. 2005, 114: 364-370. 10.1002/ijc.20750.CrossRefPubMed
10.
go back to reference Duquesne F, Florent M, Roué G, Troussard X, Sola B: Ectopic expression of cyclin D1 impairs the proliferation and enhances the apoptosis of a murine lymphoid cell line. Cell Death Different. 2001, 8: 51-62. 10.1038/sj.cdd.4400768.CrossRef Duquesne F, Florent M, Roué G, Troussard X, Sola B: Ectopic expression of cyclin D1 impairs the proliferation and enhances the apoptosis of a murine lymphoid cell line. Cell Death Different. 2001, 8: 51-62. 10.1038/sj.cdd.4400768.CrossRef
11.
go back to reference Roué G, Krieger S, Florent M, Roussel M, Duquesne F, Troussard X, Pichereau V, Sola B: Expression of the two alternative [a] and [b] transcripts of CCND1 gene in cyclin D1-expressing-malignancies: relevance for the pathogenesis. Leukemia. 2003, 17: 652-655. 10.1038/sj.leu.2402817.CrossRefPubMed Roué G, Krieger S, Florent M, Roussel M, Duquesne F, Troussard X, Pichereau V, Sola B: Expression of the two alternative [a] and [b] transcripts of CCND1 gene in cyclin D1-expressing-malignancies: relevance for the pathogenesis. Leukemia. 2003, 17: 652-655. 10.1038/sj.leu.2402817.CrossRefPubMed
12.
go back to reference Knudsen KE, Diehl JA, Haiman CA, Knudsen ES: Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006, 25: 1620-1628. 10.1038/sj.onc.1209371.CrossRefPubMed Knudsen KE, Diehl JA, Haiman CA, Knudsen ES: Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006, 25: 1620-1628. 10.1038/sj.onc.1209371.CrossRefPubMed
13.
go back to reference Bogner C, Peschel C, Decker T: Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Leuk Lymphoma. 2006, 47: 195-205. 10.1080/10428190500144490.CrossRefPubMed Bogner C, Peschel C, Decker T: Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Leuk Lymphoma. 2006, 47: 195-205. 10.1080/10428190500144490.CrossRefPubMed
14.
go back to reference Agami R, Bernards R: Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell. 2000, 102: 55-66. 10.1016/S0092-8674(00)00010-6.CrossRefPubMed Agami R, Bernards R: Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell. 2000, 102: 55-66. 10.1016/S0092-8674(00)00010-6.CrossRefPubMed
15.
go back to reference Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA: Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene. 2006, 25: 998-1007. 10.1038/sj.onc.1209147.CrossRefPubMedPubMedCentral Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA: Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene. 2006, 25: 998-1007. 10.1038/sj.onc.1209147.CrossRefPubMedPubMedCentral
16.
go back to reference Diehl JA, Sherr CJ: A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol. 1997, 17: 7362-7374.CrossRefPubMedPubMedCentral Diehl JA, Sherr CJ: A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol. 1997, 17: 7362-7374.CrossRefPubMedPubMedCentral
17.
go back to reference Carrère N, Belaud-Rotureau M-A, Dubus P, de Mascarel A, Merlio JP: The relative levels of cyclin D1a and D1b alternative transcripts in mantle cell lymphoma may depend more on sample origin than on CCND1 polymorphism. Haematologica. 2005, 90: 854-856.PubMed Carrère N, Belaud-Rotureau M-A, Dubus P, de Mascarel A, Merlio JP: The relative levels of cyclin D1a and D1b alternative transcripts in mantle cell lymphoma may depend more on sample origin than on CCND1 polymorphism. Haematologica. 2005, 90: 854-856.PubMed
18.
go back to reference Howe D, Lynas C: The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica. 2001, 86: 563-569.PubMed Howe D, Lynas C: The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica. 2001, 86: 563-569.PubMed
19.
go back to reference Hosokawa Y, Arnold A: Mechanims of cyclin D1 (CCND1, PRAD1) overexpession in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer. 1998, 22: 66-71. 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5.CrossRefPubMed Hosokawa Y, Arnold A: Mechanims of cyclin D1 (CCND1, PRAD1) overexpession in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer. 1998, 22: 66-71. 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5.CrossRefPubMed
Metadata
Title
Relevance of cyclin D1b expression and CCND1polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma
Authors
Sophie Krieger
Juliette Gauduchon
Mikel Roussel
Xavier Troussard
Brigitte Sola
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-238

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine